Sharekhan

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

What’s Your Call?

Collective community sentiment on Oxygenta Pharmaceutical Ltd

Your Vote -

Buy

50.00%

Hold

0.00%

Sell

50.00%

50.00%

2 users have voted

No Records Found

Option Chain

Analyzes market sentiment, predicts Oxygenta Pharmaceutical Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Oxygenta Pharmaceuti - Intimation Of Calendar Of Events For The Postal Ballot Process Under Regulations 30 Of SEBI (Listing O

    11 Nov 2025, 6:00PM Calendar of Events of Postal Ballot
  • Oxygenta Pharmaceuti - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

    11 Nov 2025, 5:56PM Notice of Postal Ballot - Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclsoure Requirement
  • Oxygenta Pharmaceuti posts Q2 net loss of Rs 4.93 cr

    7 Nov 2025, 6:31PM The company reported standalone net loss during the quarter stood at Rs 4.93 crore as compared to net loss of Rs 2.85 crore in the previous year quart
  • Oxygenta Pharmaceuti - Announcement under Regulation 30 (LODR)-Change in Management

    7 Nov 2025, 6:17PM Appointment of Mr. Prasad Reddy Battinapatla as Chief Financial Officer of the Company
  • Oxygenta Pharmaceuti - Un Audited Financial Results For The Quarter And Half Year Ended 30.09.2025

    7 Nov 2025, 6:13PM Un Audited financial results for the Quarter and Half year ended 30.09.2025
  • Oxygenta Pharmaceuti - Board Meeting Outcome for Outcome Of The Board Meeting Held On 07.11.2025

    7 Nov 2025, 6:07PM Outcome of the Board meeting held on 07.11.2025
  • Oxygenta Pharmaceuti - Board Meeting Intimation for 1. Un-Audited Financial Results For The Quarter And Half Year Ended Septe

    3 Nov 2025, 5:23PM Oxygenta Pharmaceutical Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2025 ,inter alia, to consi
  • Oxygenta Pharmaceuti - Disclosure Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (Listing Obligations An

    22 Oct 2025, 5:00PM Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclsoure Requirement), Regulation, 2015.
  • Oxygenta Pharmaceuti has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2025

    21 Oct 2025, 2:10PM As of September 2025, 57.95% is owned by Indian Promoters and 42.05% by Public. <p align=justify> Top five Promoters holding highest number of shares
  • Oxygenta Pharmaceuti - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    18 Oct 2025, 8:34PM Compliance as per Regulation 74(5) of SEBI(Depositories and Participants), Regulations, 2018 for the Quarter ended 30th September, 2025.
  • Oxygenta Pharmaceuti - Announcement Under Regulation 30

    16 Oct 2025, 7:01PM Intimation of Receipt of No-objection from BSE Limited (BSE) for reclassification from \Promoter/ Promoter Group\ Category to \Public\ Category shareh
  • Oxygenta Pharmaceuti - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    19 Sep 2025, 8:52PM Secrutinzers Report and Voting Results for AGM held on 19.09.2025
  • Oxygenta Pharmaceuti - Shareholder Meeting / Postal Ballot-Outcome of AGM

    19 Sep 2025, 8:48PM Outcome of the 32nd Annual General Meeting of the Company.
  • Oxygenta Pharmaceuti - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    19 Sep 2025, 8:52PM Secrutinzers Report and Voting Results for AGM held on 19.09.2025
  • Oxygenta Pharmaceuti - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    19 Sep 2025, 8:52PM Secrutinzers Report and Voting Results for AGM held on 19.09.2025
  • Oxygenta Pharmaceuti - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    19 Sep 2025, 8:52PM Secrutinzers Report and Voting Results for AGM held on 19.09.2025

Key fundamentals

Evaluate the intrinsic value of Oxygenta Pharmaceutical Ltd stock 

Name March-25 March-24 March-23 March-22 March-21
Assets 37.2076 37.1113 21.7934 17.4997 9.8685
Liabilities 37.2076 37.1113 21.7934 17.4997 9.8685
Equity 36.9835 33.4835 14.2013 14.2013 10.2013
Gross Profit -9.9947 -9.6965 -7.1168 1.4759 3.8424
Net Profit -9.6826 -3.4793 -11.5709 -0.6104 2.9298
Cash From Operating Activities 2.6028 -13.0496 -1.6336 -1.6799 -1.6219
NPM(%) -8.85 -8.77 -37.34 -1 5.63
Revenue 109.2986 39.6421 30.9874 60.5248 52.027
Expenses 119.2933 49.3386 38.1042 59.0488 48.1845
ROE(%) 49.3 17.71 58.91 3.1 -14.91

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day

Peers

Other companies within the same industry or sector that are comparable to Oxygenta Pharmaceutical Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 767.30 -1.05 0.00 33.70 301.39 0.64
Lotus Eye Hospital and Institute Ltd 105.20 0.53 330.34 122.80 3.55 0.00
Bharat Immunological and Biologicals Corporation Ltd 19.45 -2.26 0.00 254.98 -39.50 0.00
Astec Lifesciences Ltd 755.00 -7.72 0.00 115.81 -604.77 0.00

Company Info

OXYGENTA PHARMACEUTICAL LIMITED was incorporated as Private Limited Company in the year 1990 and subsequently converted into a Limited Company in 1993, with the objective of carrying on the business of manufacturing all classes and kinds of Drugs including Pharmaceutical preparation, and Organic Fine Chemicals. 1990 - The company was incorporated and its main line of business was bulk drugs. 1994 - The company had entered into an MOU with ICD group BV of Netherlands. As per the agreement, ICD would purchase 36 tonnes a year of mebadazole and 12 tonnes of atenolol for a period of five years from the company. 1998 - The company was turned sick and was registered with BIFR. 2003 -The board of the company had approved to convert the unsecured loans of Rs 2 crore into 20 lakh equity shares of Rs 10 each. - The board had also proposed to increase the authorized capital to Rs 8 crore from the existing level of Rs 6 crore. 2006 - Mr. Y Ramachandra Reddy (joint managing director), Mr. E Rama Subba Reddy (director) and Mr. G Chandramoulieswar Reddy (director) had resigned from the board of directors of the company. 2007 - Board of directors of the company on 4th April had passed the resolution to extend the financial year of the company to 15 months. 2008 - The Board of the company had appointed Mr. MG Naidu as independent director of the company. 2022 -Company name has changed to Oxygenta Pharmaceutical Ltd. from S S Organics Ltd..

OXYGENTA PHARMACEUTICAL LIMITED was incorporated as Private Limited Company in the year 1990 and subsequently converted into a Limited Company in 1993, with the objective of carrying on the business of manufacturing all classes and kinds of Drugs including Pharmaceutical preparation, and Organic Fine Chemicals. 1990 - The company was incorporated and its main line of business was bulk drugs. 1994 - The company had entered into an MOU with ICD group BV of Netherlands. As per the agreement, ICD would purchase 36 tonnes a year of mebadazole and 12 tonnes of atenolol for a period of five years from the company. 1998 - The company was turned sick and was registered with BIFR. 2003 -The board of the company had approved to convert the unsecured loans of Rs 2 crore into 20 lakh equity shares of Rs 10 each. - The board had also proposed to increase the authorized capital to Rs 8 crore from the existing level of Rs 6 crore. 2006 - Mr. Y Ramachandra Reddy (joint managing director), Mr. E Rama Subba Reddy (director) and Mr. G Chandramoulieswar Reddy (director) had resigned from the board of directors of the company. 2007 - Board of directors of the company on 4th April had passed the resolution to extend the financial year of the company to 15 months. 2008 - The Board of the company had appointed Mr. MG Naidu as independent director of the company. 2022 -Company name has changed to Oxygenta Pharmaceutical Ltd. from S S Organics Ltd..

Read More

Parent Organisation

Oxygenta Pharmaceutical Ltd.

Founded

27/11/1990

Managing Director

NSE Symbol

FAQ

The current price of Oxygenta Pharmaceutical Ltd is

The 52-week high for Oxygenta Pharmaceutical Ltd is

The market capitalization of Oxygenta Pharmaceutical Ltd is currently This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Oxygenta Pharmaceutical Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Oxygenta Pharmaceutical Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Oxygenta Pharmaceutical Ltd shares.

The CEO of Oxygenta Pharmaceutical Ltd is , who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT